Center for Gastric Cancer, National Cancer Center, Goyang, Korea.
Department of Laboratory Medicine, Asan Medical Center, Seoul, Korea.
Gut Liver. 2018 May 15;12(3):278-287. doi: 10.5009/gnl17217.
BACKGROUND/AIMS: Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach is an uncommon disease. Bone marrow involvement is reported even in patients with only a mucosal lesion. We evaluated the prevalence and risk factors of marrow involvement and its implications for diagnosis and treatment.
In total, 132 patients who were diagnosed with gastric MALT lymphoma at the National Cancer Center in Korea between January 2001 and December 2016 were enrolled in the study. The patient data were collected and analyzed retrospectively.
Of the 132 patients, 47 (35.6%) were male, with a median age of 52 years (range, 17 to 81 years). The median follow-up duration was 48.8 months (range, 0.5 to 169.9 months). infection was detected in 82 patients (62.1%). Most patients (80.3%) had stage IE1 according to the modified Ann Arbor staging system. Ninety-two patients underwent bone marrow evaluation, and four patients (4.3%) had marrow involvement. Of these patients, one presented with abdominal lymph node involvement, while the other three had stage IE1 disease if marrow involvement was disregarded. All three patients had no significant symptoms and were monitored after local treatment without evidence of disease aggravation.
Bone marrow involvement was found in 4.3% of the patients with gastric MALT lymphoma. Bone marrow examination may be deferred because marrow involvement does not change the treatment options or outcome in gastric MALT lymphoma confined to the stomach wall.
背景/目的:胃黏膜相关淋巴组织(MALT)淋巴瘤是一种罕见疾病。即使在仅有黏膜病变的患者中,也有骨髓受累的报道。我们评估了骨髓受累的患病率和危险因素及其对诊断和治疗的影响。
本研究共纳入了 2001 年 1 月至 2016 年 12 月期间在韩国国家癌症中心诊断为胃 MALT 淋巴瘤的 132 例患者。回顾性收集并分析了患者的数据。
132 例患者中,47 例(35.6%)为男性,中位年龄为 52 岁(范围 17-81 岁)。中位随访时间为 48.8 个月(范围 0.5-169.9 个月)。82 例(62.1%)患者检测到 感染。根据改良的 Ann Arbor 分期系统,大多数患者(80.3%)为 IE1 期。92 例患者进行了骨髓评估,其中 4 例(4.3%)存在骨髓受累。这 4 例患者中,1 例伴有腹部淋巴结受累,而另外 3 例如果不考虑骨髓受累,则为 IE1 期疾病。这 3 例患者均无明显症状,在局部治疗后进行监测,未发现病情恶化。
胃 MALT 淋巴瘤患者中有 4.3%存在骨髓受累。由于骨髓受累不会改变局限于胃壁的胃 MALT 淋巴瘤的治疗选择或结局,因此可能会推迟骨髓检查。